Feed COCP
CO

Cocrystal Pharma, Inc.

COCP · NASDAQ

$1.22 +0.41% (+$0.01)
1M +9.01%
Market Cap $16.8M
P/E Ratio -
Div. Yield -
ROE 207.47%

Bulios Fair Price

$0.68

44.0% downside

Current Price

$1.22

Undervalued Fair Value Overvalued

According to Bulios Fair Price, COCP is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
3/9
Valuation
0 /100
Expensive
P/S 50.76x
P/B 16.05x
P/E N/A
Growth
0 /100
Declining
Book val. growth 45.71%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak
Gross margin 205.76%
FCF margin 2,470.67%
Net margin 3,011.52%
Quality
1 /100
Poor
ROIC 423.90%
Asset turnover 0.07x
ROE 207.47%
Debt
45 /100
Moderate
Debt/Equity 1.28x
Current ratio 1.24x
Int. coverage N/A
Stability
14 /100
Unstable
Beta 1.48x
Profitable years 0
EPS volatility 52,252.30%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about COCP
Online

About the company

Cocrystal Pharma, Inc. (COCP) is a biotechnology company focusing on the discovery and development of antiviral drug compounds to combat infectious diseases. The company specializes in developing therapeutic products that target the inhibition of virus replication and prevent their spread. Cocrystal Pharma develops drugs for various viral infections, including diseases like influenza, upper respiratory tract infections, and more. The company utilizes structural biology and computational modeling to design effective drug compounds. With the growing significance of antiviral drugs and the need for new treatment options, Cocrystal Pharma, Inc. has the potential for sustained growth. Cocrystal Pharma, Inc. (COCP) shares might be an interesting choice for investors seeking involvement in the biotechnology and antiviral therapeutic therapies industry.

Sector

Healthcare

Industry

Biotechnology

CEO

James E. Sapirstein

Employees

10

Headquarters

Bothell

Upcoming events

13 NOV

Earnings

Upcoming earnings report

52d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.